CMR Surgical sells first Versius robot, in India

CMR Surgical said today that it completed the first sale of its Versius robotic surgical system […]

CMR Surgical said today that it completed the first sale of its Versius robotic surgical system to the Galaxy Care Hospital in Pune, India.
Versius is designed for use in minimal-access procedures; at Galaxy Care those ranged from transthoracic procedures to hysterectomies and myomectomies, led by Dr. Shailesh Puntambekar, according to a news release.
Cambridge, U.K.-based CMR Surgical said it is also launching the world’s first clinical registry for a surgical robotic system as part of its post-market surveillance. The registry is designed to record and monitor patient outcomes of all Versius procedures, including operative time, length of stay, return to hospital within 30 days and return to operating room within 24 hours.
CMR Surgical said it anticipates the first sale of the Versius system will be followed by introduction of the platform across Europe by the end of 2019. CMR Surgical unveiled the Versius system in September 2018.
“As an experienced surgeon in robotic assisted surgery I think that there is significant potential for Versius to further increase access to laparoscopic surgery for my patients, so it was a natural choice to acquire this system,” Puntambekar said in prepared remarks. “Versius, as a small and cost-effective system is well suited for meeting the high surgical demand in India. We are excited to bring the next-generation surgical robot to India.”
“Galaxy Care has become our first customer to acquire and use Versius and this is an important milestone in bringing the benefits of minimal access surgery to all,” added CMR chief medical officer Mark Slack. “We are pleased to be working with a centre that has some of the best surgeons in the world, meeting a high surgical demand. It is important that we bring Versius to market responsibly and we are delighted to be working closely with Galaxy Care on the introduction of Versius in the hospital.”
The Versius system’s commercialization was aided by a $243 million Series C funding round last month. The company said at the time that the funding was Europe’s largest private medtech financing.
That funding came after the Versius’ first in-human procedures were performed in May. The system was used for minor and major gynecological and upper gastrointestinal procedures and no adverse events were reported related to the Versius system at 30-days post procedure.
Original Article: (